Cyanocobalamin
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
- Cyanocobalamin
- Pharmacist Assessment Report
- Cyanocobalamin: From Vitamin B12 Deficiency to Biotin Metabolic Disease
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Cyanocobalamin: From Vitamin B12 Deficiency to Biotin Metabolic Disease
One-Sentence Summary
Cyanocobalamin (vitamin B12) was originally used to treat vitamin B12 deficiency and related anaemias, including pernicious anaemia. The TxGNN model predicts it may be effective for biotin metabolic disease, but this is a computational prediction only, with no clinical trials and 1 publication (a general review of vitamin production, not clinical evidence) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Vitamin B12 deficiency, pernicious anaemia, folic acid deficiency anaemia, iron deficiency anaemia, and other deficiency anaemias (per the TxGNN knowledge graph; no approved indication text is recorded for the ARTG entry) |
| Predicted New Indication | Biotin metabolic disease |
| TxGNN Prediction Score | 0.9960 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the data compiled for this report. Based on established pharmacology, cyanocobalamin is a cobalamin cofactor for methionine synthase and methylmalonyl-CoA mutase. Its efficacy in B12 deficiency and pernicious anaemia is well established.
The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. No direct mechanism has been shown by which cyanocobalamin corrects a primary biotin metabolic defect, such as biotinidase deficiency or holocarboxylase synthetase deficiency. The standard treatment for those disorders is biotin supplementation. The prediction should therefore be treated as a hypothesis-generating signal, not a supported therapeutic link.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 1368195 | 1992 | Review | Journal of Chemical Technology and Biotechnology | Overview of biotechnological production of vitamins and coenzymes. It does not assess clinical efficacy in biotin metabolic disease. |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 4493L | Accomin Adult Tonic | Oral liquid 200 mL | Not recorded in the data compiled for this report |
Safety Considerations
Drug Interactions: The interaction screen identified 313 potential interactions. The entries listed are mostly minor or of unknown severity:
- Minor: acid-suppressing agents, including famotidine, ranitidine, cimetidine, nizatidine, and the proton pump inhibitors (omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, rabeprazole). Potassium chloride is also listed as minor.
- Unknown severity: metformin, glimepiride, acarbose, rosiglitazone, mesalazine, doxycycline, morphine, and sucralfate.
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications, as none were available in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high, but it is model-based only (L5). There are no registered trials, the only publication is an unrelated production-process review, and no mechanism links cyanocobalamin to correcting a biotin metabolic defect. Biotin supplementation is already the standard treatment.
To proceed, the following is needed:
- Mechanism of action data to test the proposed link
- Preclinical or mechanistic studies showing a biological effect in biotin-related pathways
- Case series or clinical studies in biotinidase or holocarboxylase synthetase deficiency, if the hypothesis is pursued
- The approved indication text and the PI warnings and contraindications for the ARTG entry
- Review of the clinical relevance of the interactions flagged above
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.